Ovarian cancer remains one of the most challenging malignancies in gynecologic oncology. Often diagnosed at an advanced stage, it is the fifth leading cause of cancer-related death among women in the Western world. Over 20,000 new cases of ovarian cancer were diagnosed in the United States in 2024, with more than 12,000 women predicted to die from the disease each year [1]. The five-year survival rate remains below 30% in advanced stages, primarily due to late detection and high recurrence rates following standard treatments such as surgery and chemotherapy.
But there is hope. Modern treatment approaches help patients improve progression-free survival up to 80%. One of these treatments is a dendritic cell vaccine for ovarian cancer. In 2011, American immunologist Ralph Steinman received the Nobel Prize for the discovery of dendritic cells, which laid the groundwork for a new approach to immunotherapy [2].
What is Ovarian Cancer?
Ovarian cancer is a malignant tumor that develops in the ovaries – the small, almond-shaped organs located on either side of the uterus, responsible for producing eggs and female hormones. Although it is not the most common gynecologic cancer, it causes more deaths than any other cancer of the female reproductive system.
Like many cancers, ovarian cancer is classified into four stages [3]:
- Stage I is limited to one or both ovaries.
- Stage II involves spread to the pelvic region.
- Stage III includes metastasis to the abdominal lining or lymph nodes.
- Stage IV, the most advanced, indicates distant metastasis, such as to the liver or lungs.
One of the most difficult aspects of ovarian cancer is its subtle onset. Early symptoms – such as bloating, pelvic discomfort, or changes in urination – are often vague and mistaken for benign conditions. There is currently no reliable screening test for ovarian cancer in asymptomatic women, and CA-125 blood levels, while useful, are not specific enough to serve as a standalone diagnostic tool.
By the time ovarian cancer is diagnosed, more than 70% of patients are already in stage III or IV [4]. While standard therapies such as surgery and chemotherapy may initially reduce tumor burden, relapse is frequent and often more resistant to conventional drugs. This has led leading cancer centers to adopt more personalized approaches – such as dendritic cell vaccines – that aim to enhance the immune system’s ability to recognize and control residual or recurrent disease.
Dendritic Cells and the Basis of Dendritic Cell Therapy in Ovarian Cancer
The immune system is remarkably good at recognizing what doesn’t belong in the body. Every day, it scans for viruses, bacteria, and mutated cells – and in many cases, it catches problems before they become serious. But cancer often finds ways to slip through the cracks, hiding from immune surveillance or actively suppressing it. This is where a vaccine for ovarian cancer comes in – offering a way to reawaken the immune system and direct its attention where it’s needed most.
Dendritic cells (DC) are sometimes called the "sentinels" of the immune system. Their job is to detect danger, pick up pieces of abnormal material – like cancer antigens – and present that information to T-cells, which are the immune system’s attack force [5]. Without DC, the immune system can’t respond in a targeted way. They act as the bridge between detection and action. Often, the tumor microenvironment releases immunosuppressive cytokines that prevent them from developing and growing, a phenomenon known as tumor-induced dysfunction of the dendritic cell. Immunotherapy in ovarian cancer helps overcome these limitations of the natural recognition of cancer and restores an adequate immune response.
How the Dendritic Cell Vaccine for Ovarian Cancer Works
In immunotherapy, scientists take advantage of this natural function. The process usually begins by collecting a patient’s own immune cells – typically through a simple blood draw. In the lab, dendritic cells are isolated and "trained" by exposing them to tumor-specific antigens. Once these cells have been properly loaded, they are reintroduced into the patient’s body, where they act like messengers – activating T-cells to recognize and attack cancer cells.
The ovarian cancer vaccine is highly personalized because it is made using the patient’s own cells and tumor material. It's also a strategic form of therapy for advanced ovarian cancer: instead of killing cancer directly, it empowers the immune system to do so more intelligently and precisely. Over the past two decades, DC therapy has been explored in various cancers – including melanoma, prostate cancer, glioblastoma, and others – showing increasing evidence of safety and immune system activation.
The Clinical Value of Dendritic Cell Therapy in Ovarian Cancer Treatment
Numerous scientific studies and real-world applications have confirmed that dendritic cell vaccines improve progression-free survival and overall survival rates in ovarian cancer patients. Their personalized nature minimizes side effects common to chemotherapy and supports long-term immune memory, reducing the risk of disease recurrence. Ovarian cancer vaccines are rapidly becoming a standard recommendation in specialized cancer centers worldwide.
What Makes DC Therapy Different from Other Ovarian Cancer Immunotherapies?
Unlike checkpoint inhibitors, which simply release the brakes on T-cells already in action, or CAR T-cell therapy, which modifies T-cells directly, ovarian cancer vaccine therapy works a step earlier. It rebuilds the conversation between the innate and adaptive parts of the immune system, helping the body spot tumors it might have missed before [7].
What’s really cool about vaccine therapy for ovarian cancer is how personal it is. The DCs are "taught" using antigens taken from the patient’s own tumor, so the immune system learns exactly what to attack. This means fewer side effects and a better chance that the immune system will remember and keep fighting the cancer over time.
DC also doesn’t just send messages from afar – they actually get inside the tumor itself. Detailed imaging shows that mature dendritic cells can enter the tumor, contact cancer cells, and help shape the local immune response to support the fight against the tumor.
The Use of Dendritic Cell Therapy in Ovarian Cancer at Different Stages
Dendritic cell therapy has become an integral part of modern treatment, especially in cases where conventional therapies alone are insufficient. Their unique ability to harness and direct the patient’s immune system allows for precise targeting of tumor cells, improving disease control and reducing the risk of recurrence.
This new vaccine for ovarian cancer has proven to be most effective when administered during specific phases of treatment, particularly after initial debulking surgery and chemotherapy. This timing is crucial because it coincides with a period of minimal residual disease – when the bulk of the tumor has been removed or reduced, and only a small number of cancer cells remain. At this stage, the patient’s immune system is in an optimal state to be activated and trained to recognize any leftover cancer cells, thereby significantly reducing the risk of relapse.
The combination of surgery, chemotherapy, and dendritic cell vaccination creates a powerful multi-pronged approach for ovarian cancer treatment. Vaccine steps in to stimulate a tailored immune response, effectively "teaching" the body’s defenses to seek out and destroy any cancer cells that survive standard treatments. Surgery physically removes as much tumor mass as possible, while chemotherapy targets rapidly dividing cells to further reduce tumor burden.
Importantly, dendritic cell vaccination is not limited to early or intermediate disease phases. Studies show that even in advanced or recurrent cases – where traditional therapies often fail to induce durable remission – DCV offers meaningful benefits [8]. By re-engaging the immune system, dendritic cell vaccines provide a new line of attack against tumors that have developed resistance to chemotherapy or other treatments.
Through careful coordination with other therapeutic phases, DC vaccination enhances overall treatment effectiveness and improves outcomes for patients facing the challenges of ovarian cancer across various stages.
Side Effects and Contraindications of Dendritic Cell Therapy
The DC vaccine for ovarian cancer is mostly considered a safe and well-tolerated procedure. It is all because the vaccine is developed from the patient's own immune cells, which almost eliminates allergic responses.
Like any vaccine, it can cause some side effects, including:
- Swelling at the injection site
- Short-term chills
- Low fever
- Fatigue
- Headache
But there are some cases where DCV cannot be used safely [10]:
- High-grade immunodeficiency with low white blood cell count
- Organ failure, or if the patient is an organ transplant recipient
- Hematologic malignancies, where the tumor directly suppresses dendritic cell function
- Severe autoimmune conditions
When choosing a DC vaccination, it is important to gather all the necessary information about benefits and limitations to achieve the best possible outcomes for your specific case. For that reason, we present a comparison table between traditional treatment approaches and a DCV to help you understand all the benefits of receiving this modern ovarian cancer vaccine.
| Treatment option | Indications | Side effects | Disadvantages | Benefits |
|---|---|---|---|---|
| Dendritic cell therapy | all malignant tumors of all stages | minimal (flu-like symptoms) | individualized manufacturing is available at specialized centers only | highly personalized, life-long immunity after a single injection, minimal side effects |
| Standard immunotherapy: without individual production | specific malignant tumors of all stages | mild to moderate (rash, fatigue) | risk of severe immune-related adverse events, high proportion of non-responders, need for continuous long-term treatment | no need for patient-specific cell production, broader availability across treatment centers |
| Chemotherapy | malignant tumors of all stages | severe (nausea, hair loss) | systemic side effects, low quality of life during treatment, development of resistance over time, and high recurrence rate | widely available, effective for systemic disease, temporarily slows tumor growth |
Step-by-Step Process of Dendritic Cell Therapy for Ovarian Cancer
The microenvironment created by the tumor can interfere with natural recognition of the malignancy, which allows cancer to grow. DCV is a highly personalized, technology-driven procedure that can solve this problem. The process is quite simple and easy for the patient to understand compared with other treatments. Ovarian cancer vaccine can be administered at any stage of the personalised therapy plan and effectively complements all other forms of oncological care. All that is needed to create the DCV is a blood sample from the patient and tumor particles, which can be obtained through liquid biopsy.
The procedure may differ slightly between oncological centers depending on your specific case. But it is usually performed this way:
Day 1 (30min): You arrive at the first appointment at the clinic. You will discuss your medical history with your doctor and undergo a thorough examination. The medical team will talk to you about other possible therapeutic options, nutrition, and complementary medicines. Then you will make an informed consent to receive the DCV.
Day 2 (90min): During this morning appointment, 150 - 200ml of blood will be drawn for the vaccine creation. Then a vitamin C and vitamin B-complex infusion will be administered, followed by an intramuscular vitamin D injection (50.000 IU). This is done to stimulate your immune cells, especially NK cells, to prepare your body for vaccination. An important note is that you can have breakfast before blood collection.
Day 9 (90min): By this time, the vaccine therapy for ovarian cancer is ready to be administered. Patient arrives around noon and can have a meal beforehed. The vaccine is injected intradermally, followed by the vitamin C and vitamin B-complex infusion. Furthermore, a 50.000 IU intramuscular vitamin D injection is given.
As a further recommendation, patients are advised to supplement vitamin D orally at 40.000 IU per week to strengthen their immune system.
The process of DC vaccination is transparent and easy to undergo even for patients with advanced forms of the disease. This makes this ovarian cancer treatment vaccine stand out among other therapies. It provides amazing results with limited side effects, which is really important for patients who can be weakened and tired by standard, more invasive procedures.
Clinics for Dendritic Cell Therapy for Ovarian Cancer in Germany
The dendritic cell therapy ovarian cancer patients can receive is not available in many countries. This is due to the need for advanced laboratory equipment, strict regulatory approval, and GMP-compliant cell processing facilities, which require top specialists and scientists in the field to create personalized cancer vaccines from the patient’s own immune cells. The treatment is performed in selected centers in Switzerland, Japan, and the United States, but it is most developed in Germany.
Ovarian cancer vaccine, Germany offers, is available in several hospitals throughout the country, making them the most experienced in the world. Hospitals in Germany are known for their high standards and comprehensive cancer care programs. When it comes to DC vaccine and ovarian cancer treatment in general, Germany stands out thanks to specialized centers that integrate DCV into multidisciplinary treatment plans. These hospitals employ experienced oncologists, immunologists, and radiologists who collaborate closely to tailor treatments for each patient’s unique case.
Take a look at some facilities that provide state-of-the-art diagnostic tools as well as therapies like DCV:
- Laboratories Dr. Gansauge in Berg. This clinic has worldwide recognition for its exceptional experience and success rates in DC therapy. They integrate advanced research into comprehensive treatment plans with emphasis on the patient’s comfort and quality of life.
- IOZK Immuno-Oncology Center in Cologne. This is a well-established immunology center that integrates dendritic cell vaccination with other treatments to achieve the best results and extend survival.
- Praxisgemeinschaft für Zelltherapie in Duderstadt. It’s a German modern research facility for molecular therapies, including DCV. They aim to provide a personalised strategy delivered through advanced laboratory technologies.
Patients traveling abroad for personalized cancer immunotherapy choose German hospitals for their commitment to innovation and patient-centered care. Whether you are seeking initial treatment or advanced care for ovarian cancer, Germany’s integrated healthcare system offers access to dendritic cell vaccines combined with surgery, chemotherapy, and other immunotherapies. This comprehensive approach optimizes the effectiveness of your treatment plan and supports long-term health.
Cost of Dendritic Cell Therapy for Ovarian Cancer in Germany
An ovarian cancer vaccine cost vary significantly depending on the country, clinic, and healthcare system. Because this therapy is personalized and requires specialized laboratory preparation of immune cells, it is generally more expensive. In countries like the United States, it is not yet a standard practice and may involve lengthy wait times, sometimes extending several months.
For cancer patients considering dendritic cell therapy, Germany provides an unmatched environment – balancing innovation, quality, and accessibility – to ensure the best possible outcome. One of the main benefits is the treatment's price. It ranges from €20,000 to €38,000, compared to the United States, where it is estimated at €100,000 to €150,000. In Great Britain and Australia, dendritic cell therapy isn't widely accessible.
Take a moment to see how DCV prices compare in different countries.
| Country | Dendritic cell therapy price |
|---|---|
| Germany | €20,000 - €38,000 |
| USA | €100,000 - €150,000 |
| Great Britain | Not available |
| Australia | Not available |
* Costs are approximate and may vary depending on the hospital and individual patient requirements.
Increasing the Effectiveness of Dendritic Cell Therapy by Combining It with Other Treatments
Standard treatment for ovarian cancer typically involves a combination of surgery and systemic therapy. Understanding the strengths and weaknesses of conventional options is key to appreciating the role of more individualized therapies, such as dendritic cell vaccines, for ovarian cancer. Some of those therapies are:
- Surgery. Known as debulking or cytoreductive surgery, it is often the first major step in treating ovarian cancer. The goal is to remove as much visible cancer as possible.
- Chemotherapy. Typically, a combination of drugs can shrink tumors and delay progression, especially early in the treatment course. But many tumors become resistant, and side effects such as fatigue, nausea, neuropathy, and immune suppression can make treatment more difficult with each recurrence.
- Targeted therapies. PARP inhibitors are especially beneficial for women with BRCA1/2 mutations or homologous recombination deficiency (HRD). These drugs can help delay progression in certain subtypes of ovarian cancer, but they are not universally effective and are often used in combination with other treatments.
Despite advances in surgery and chemotherapy, recurrence remains a major challenge. Standard treatments often fail to eliminate microscopic disease that can later grow and spread. These limitations are driving greater interest in modern immunotherapies, such as dendritic cell vaccines.
Rather than replacing conventional methods, DCV works hand in hand with established treatments to create a more effective and comprehensive strategy. Dendritic cell vaccines play a critical role in helping the immune system identify and eliminate residual tumor cells. To achieve the best results, ovarian cancer vaccines can be combined with:
- Chemotherapy. Its ability to reduce tumor burden not only shrinks the cancer but also exposes tumor antigens that might otherwise remain hidden from immune detection. This creates an ideal environment for the dendritic vaccine to prime the immune system, essentially "teaching" immune cells to recognize these tumor-specific markers. As a result, patients with advanced ovarian cancer receive a boost in their immune response targeted specifically at ovarian cancer cells, increasing the chance of durable remission.
- Surgery. When combined with surgery, the dendritic vaccine mobilizes the body’s immune defenses to seek out and destroy remaining cancer cells. This layered approach not only improves patient outcomes but also reduces the likelihood of relapse by engaging the immune system in a sustained fight against the disease.
- Regional chemotherapy (RC). RC first reduces tumor burden by delivering high concentrations of cytotoxic drugs directly to the tumor site. The combination with DCV improves local tumor control by systemically targeting residual tumors.
- Hyperthermia. Localized heating attracts more immune cells to the tumor area, resulting in a stronger immune response and improved effectiveness of the dendritic cell vaccine. Ovarian cancer patients can benefit from this combination, as it can stimulate immune activity and increase the sensitivity of tumor cells to immune-mediated destruction.
For patients facing late-stage ovarian cancer, this combination offers renewed hope. A dendritic cell vaccine provides a personalized, immune-driven approach that complements traditional treatments, transforming how ovarian cancer is managed today. As a result, cancer patients benefit from an integrated treatment plan that harnesses the full power of their own immune system to control and suppress their cancer.
Dendritic Cell Therapy for Ovarian Cancer in Germany with Booking Health
Finding the best treatment strategy for your clinical situation is a challenging task. Being already exhausted from multiple treatment sessions, having consulted numerous specialists, and having tried various therapeutic interventions, you may be lost in all the information given by the doctors. In such a situation, it is easy to choose a first-hand option or follow standardized therapeutic protocols that carry a long list of adverse effects, rather than selecting highly specialized, innovative treatment options.
To make an informed choice and receive a personalized ovarian cancer management plan with dendritic cell vaccination tailored to your specific clinical situation, consult medical experts at Booking Health. Having been at the forefront of offering the latest medical innovations for 12 years, Booking Health possesses solid expertise in creating complex cancer management programs for each case. As a reputable company, Booking Health offers personalized ovarian cancer treatment plans with direct clinic booking and full support at every stage, from organizational processes to assistance during treatment. We provide:
- Assessment and analysis of medical reports
- Development of the medical care program
- Selection of a suitable treatment location
- Preparation of medical documents and forwarding to a suitable clinic
- Preparatory consultations with clinicians for the development of medical care programs
- Expert advice during the hospital stay
- Follow-up care after the patient returns to their native country after completing the medical care program
- Taking care of formalities as part of the preparation for the medical care program
- Coordination and organization of the patient's stay in a foreign country
- Assistance with visas and tickets
- A personal coordinator and interpreter with 24/7 support
- Transparent budgeting with no hidden costs
Health is an invaluable aspect of our lives. Delegating management of something so fragile yet precious should be done only to experts with proven experience and a reputation. Booking Health is a trustworthy partner that helps you pursue better health and a higher quality of life. Contact our medical consultant to learn more about the possibilities of personalized treatment with dendritic cell vaccination for ovarian cancer with leading specialists in this field.
Dendritic Cell Innovation: Cancer Treatment with Booking Health
Frequently Asked Questions About Dendritic Cell Therapy for Ovarian Cancer
Send request for treatmentA dendritic cell vaccine is a personalized immunotherapy that uses the patient’s own dendritic cells to stimulate immune activation. These cells train the immune system to recognize and attack cancer cells by presenting tumor-specific antigens, enhancing precise tumor targeting.
Dendritic cell therapy activates the immune system by using cancer vaccines created from a patient’s cells. It boosts the immune response to ovarian tumors, helping the body recognize and destroy cancer cells more effectively, especially in advanced or metastatic stages.
Yes. Even in stage 4 or metastatic ovarian cancer, dendritic cells can enhance immune activation and improve tumor targeting. Combined with other treatments, this personalized immunotherapy supports better disease control and can extend survival.
Dendritic cell vaccines are generally well tolerated. Side effects are usually mild and may include low-grade fever or fatigue. Because they harness the patient’s own immune system, these cancer vaccines cause fewer adverse reactions than traditional chemotherapy.
Patients with ovarian cancer at various stages, including those with advanced or metastatic disease, are eligible. Personalized immunotherapy is tailored for each patient’s unique cancer characteristics.
Yes. Combination therapy with chemotherapy and dendritic cell vaccines is common. Chemotherapy reduces tumor burden and exposes antigens, allowing dendritic cells to better activate the immune response for improved cancer control.
Germany’s advanced medical centers offer state-of-the-art diagnostics and treatment in dendritic cell vaccines. Personalized immunotherapy in German hospitals is supported by expert teams, ensuring high-quality care and innovative approaches to cancer treatment.
Booking Health support makes it easy to access dendritic cell therapy in Germany. The Booking Health team assists with choosing the right clinic, organizing medical documents, and scheduling your treatment. With Booking Health, international patients receive end-to-end support for a smooth and personalized experience.
Clinical data show that the two-year survival rate for patients with recurrent or refractory ovarian cancer after dendritic cell therapy is 60% compared to 25–35% with standard treatment. This represents a doubling of the chances of a long, progression-free life.
Dendritic cell therapy provides immune activation of T cells with a response rate of 45–65% compared to less than 20% with standard methods. This proves that the vaccine effectively triggers an antitumor immune response even in advanced or chemotherapy-resistant processes.
Yes, these are the patients who benefit the most. The therapy is able to activate the immune system even after numerous courses of chemotherapy, when the tumor becomes insensitive to drugs. Thanks to this it is possible to achieve long-term remission or stabilization of the disease.
Unlike chemotherapy which is toxic to the body, dendritic cell vaccine stimulates natural immunity to fight the tumor. It is created from the patient's own cells which provides a personalized approach and minimal side effects without damaging healthy tissues.
Unlike severe systemic complications after chemotherapy (nausea, anemia, infections), dendritic cell vaccine usually causes only mild reactions: redness of the skin, short-term fatigue or fever for 24–48 hours. The treatment is easily tolerated.
Because it activates the body's own immune system to fight tumor cells, improves survival, reduces relapses and has virtually no toxic effects. This method allows you to treat even complex forms of cancer when standard therapy no longer gives the expected result.
In Germany, ovarian cancer patients receive dendritic cell therapy only after careful evaluation. Treatments are individualized and administered under close supervision. Also, they are combined with standard oncology care to enhance immune response.
An anticancer vaccine for ovarian cancer is a type of immunotherapy that teaches your immune system to recognise the tumor and kill it. It is made from patients’ own dendritic cells, prepared in a laboratory using specific tumor antigens, and then injected back into the body to activate the T-cell response.
Cell based cancer vaccines for ovarian tumors have a personalized approach and teach the immune system to target only malignant cells. On the other hand, chemotherapy, when used systemically, damages all rapidly dividing cells, including both cancer and some healthy tissues.
The cost varies based on the treatment center, the equipment used, and any additional therapies alongside dendritic cell therapy. Ovarian cancer patients can greatly benefit from how affordable and available DCV is for international patients.
Ovarian cancer vaccine, Germany provides, is considered among the most advanced treatments in the world. Patients undergo state-of-the-art diagnostic tests that determine precise tumor profiling for ovarian cancer treatment. Vaccine is developed in modern laboratories, ensuring high standards and maximum effectiveness.
Choose treatment abroad and you will for sure get the best results!
Authors:
This article was edited by medical experts, board-certified doctors Dr. Nadezhda Ivanisova, and Dr. Yana Dmytryshyn. For the treatment of the conditions referred to in the article, you must consult a doctor; the information in the article is not intended for self-medication!
Our editorial policy, which details our commitment to accuracy and transparency, is available here. Click this link to review our policies.
Sources:
[1] Qingyuan Zhuang, Gaocheng Gu, Jiyu Chen et al. Global, regional, and national burden of ovarian cancer among young women during 1990-2019. Eur J Cancer Prev. 2025 Jan 1;34(1):1-10. doi: 10.1097/CEJ.0000000000000899. Epub 2024 Jun 4. [DOI] [PubMed]
[2] Roman Volchenkov, Florian Sprater, Petra Vogelsang, Silke Appel. The 2011 Nobel Prize in physiology or medicine. Scand J Immunol. 2012 Jan;75(1):1-4. doi: 10.1111/j.1365-3083.2011.02663.x. [DOI] [PubMed]
[3] Beata Smolarz, Karolina Biernacka, Honorata Łukasiewicz et al. Ovarian Cancer—Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors’ Molecular Backgrounds. Int J Mol Sci. 2025 May 12;26(10):4611. doi: 10.3390/ijms26104611. [DOI] [PMC free article]
[4] Rajendra Kumar Meena, Nisar Ahmad Syed, Zahoor Ahmad Sheikh et al. Patterns of Treatment and Outcomes in Epithelial Ovarian Cancer: A Retrospective North Indian Single-Institution Experience. JCO Glob Oncol. 2022 Nov 4;8:e2200032. doi: 10.1200/GO.22.00032. [DOI] [PMC free article]
[5] Antoni Ribas. Adaptive immune resistance: How cancer protects from immune attack. Cancer Discov. 2015 Aug 13;5(9):915–919. doi: 10.1158/2159-8290.CD-15-0563. [DOI] [PMC free article]
[6] Xi Zhang, Tianhui He, Yuan Li, Ling Chen, Hongyu Liu, Yu Wu, Hongyan Guo. Dendritic Cell Vaccines in Ovarian Cancer. Front Immunol. 2021 Jan 25:11:613773. doi: 10.3389/fimmu.2020.613773. eCollection 2020. [DOI] [PubMed]
[7] Heung Kyu Lee, Akiko Iwasaki. Innate control of adaptive immunity: dendritic cells and beyond. Semin Immunol. 2007 Feb;19(1):48-55. doi: 10.1016/j.smim.2006.12.001. Epub 2007 Feb 5. [DOI] [PubMed]
[8] Mohsen Sheykhhasan, Amirhossein Ahmadieh-Yazdi, Reza Heidari et al. Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy. Biomed Pharmacother. 2025 Mar:184:117858. doi: 10.1016/j.biopha.2025.117858. Epub 2025 Feb 16. [DOI] [PubMed]
[9] Aarushi Audhut Caro, Sofie Deschoemaeker, Lize Allonsius, An Coosemans, Damya Laoui. Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer. Cancers (Basel) . 2022 Aug 21;14(16):4037. doi: 10.3390/cancers14164037. [DOI] [PubMed]
[10] Steve Boudewijns, Harm Westdorp, Rutger H T Koornstra et al. Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. J Immunother. 2016 Jul-Aug;39(6):241-8. doi: 10.1097/CJI.0000000000000127. [DOI] [PubMed]
Read:
Ovarian Cancer Treatment Options in Germany
Treatment of stage 4 ovarian cancer in Germany
Top 10 Leading Oncology Hospitals for Cancer Treatment in Germany
